[
  {
    "ts": null,
    "headline": "ServiceTitan Down 39%, but This $8 Million Buy Lifted One Fund's Stake to a 16% Portfolio Bet",
    "summary": "ServiceTitan offers cloud-based workflow tools for service providers, driving digital transformation across the field service industry.",
    "url": "https://finnhub.io/api/news?id=626c4521e1a5380003771ee3ffb5923def398f58d398e09d105db9fbf6e08810",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771622258,
      "headline": "ServiceTitan Down 39%, but This $8 Million Buy Lifted One Fund's Stake to a 16% Portfolio Bet",
      "id": 139163912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "ServiceTitan offers cloud-based workflow tools for service providers, driving digital transformation across the field service industry.",
      "url": "https://finnhub.io/api/news?id=626c4521e1a5380003771ee3ffb5923def398f58d398e09d105db9fbf6e08810"
    }
  },
  {
    "ts": null,
    "headline": "Belden Stock Up 27% as $11 Million New Stake Signals Confidence in $2.7 Billion Revenue Run",
    "summary": "Belden Inc. delivers connectivity and signal transmission solutions for critical infrastructure, data centers, and industrial automation.",
    "url": "https://finnhub.io/api/news?id=47151c1adf33199abf2a3ad9b90ac9af952c1c042471742f85cc5367829ad6cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771621757,
      "headline": "Belden Stock Up 27% as $11 Million New Stake Signals Confidence in $2.7 Billion Revenue Run",
      "id": 139163913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "Belden Inc. delivers connectivity and signal transmission solutions for critical infrastructure, data centers, and industrial automation.",
      "url": "https://finnhub.io/api/news?id=47151c1adf33199abf2a3ad9b90ac9af952c1c042471742f85cc5367829ad6cb"
    }
  },
  {
    "ts": null,
    "headline": "AI Bust or a Once-in-a-Decade Buying Opportunity for This Software Stock?",
    "summary": "This stock genuinely offers investors an opportunity to buy into a growth story at a very reasonable valuation.",
    "url": "https://finnhub.io/api/news?id=ad2ce17747a41814bd062e0161086f7006f702ae521528606a6d1edd022a9f0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771565700,
      "headline": "AI Bust or a Once-in-a-Decade Buying Opportunity for This Software Stock?",
      "id": 139155396,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "This stock genuinely offers investors an opportunity to buy into a growth story at a very reasonable valuation.",
      "url": "https://finnhub.io/api/news?id=ad2ce17747a41814bd062e0161086f7006f702ae521528606a6d1edd022a9f0b"
    }
  },
  {
    "ts": null,
    "headline": "PTC Therapeutics Q4 Earnings Call Highlights",
    "summary": "PTC Therapeutics (NASDAQ:PTCT) reported fourth-quarter and full-year 2025 results highlighted by the initial global approvals and early launch performance of Sephience for phenylketonuria (PKU), which management described as the company’s “foundational product” for near-term growth. 2025 results an",
    "url": "https://finnhub.io/api/news?id=edb0756ef027f7958a9a104b42eec0c153287d13b36bab9e332078a215a06fda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771560520,
      "headline": "PTC Therapeutics Q4 Earnings Call Highlights",
      "id": 139155471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "PTC Therapeutics (NASDAQ:PTCT) reported fourth-quarter and full-year 2025 results highlighted by the initial global approvals and early launch performance of Sephience for phenylketonuria (PKU), which management described as the company’s “foundational product” for near-term growth. 2025 results an",
      "url": "https://finnhub.io/api/news?id=edb0756ef027f7958a9a104b42eec0c153287d13b36bab9e332078a215a06fda"
    }
  }
]